Related Experiment Video
Updated: Apr 11, 2026
Cheek Injection Model for Simultaneous Measurement of Pain and Itch-related Behaviors
Published on: September 27, 2019
Salvinorin A analogues PR-37 and PR-38 attenuate compound 48/80-induced itch responses in mice
M Salaga1, P R Polepally2, M Zielinska1
1Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, Lodz, Poland.
Background And Purpose:
The opioid system plays a crucial role in several physiological processes in the CNS and in the periphery. It has also been shown that selective opioid receptor agonists exert potent inhibitory action on pruritus and pain. In this study we examined whether two analogues of Salvinorin A, PR-37 and PR-38, exhibit antipruritic properties in mice.
Experimental Approach:
To examine the antiscratch effect of PR-37 and PR-38 we used a mouse model of compound 48/80-induced pruritus. In order to elucidate the mechanism of action of tested compounds, specific antagonists of opioid and cannabinoid receptors were used. The effect of PR-37 on the CNS was assessed by measuring motor parameters and exploratory behaviours in mice.
Key Results:
PR-37 and PR-38, jnjected s.c., significantly reduced the number of compound 48/80-induced scratching behaviours in mice in a dose- and time-dependent manner. PR-38 was also active when orally administered. The antiscratch activity of PR-37 was blocked by the selective κ opioid receptor antagonist, nor-binaltorphimine, and that of PR-38 by the selective μ opioid receptor antagonist, β-funaltrexamine.
Conclusion And Implications:
In conclusion, a novel framework for the development of new antipruritic drugs derived from salvinorin A has been validated.
